1. Market Research
  2. > Biotechnology Market Trends
  3. > VLP Biotech, Inc. - Product Pipeline Review - 2013

VLP Biotech, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 19 pages

VLP Biotech, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “VLP Biotech, Inc. - Product Pipeline Review - 2013” provides data on the VLP Biotech, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, VLP Biotech, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from VLP Biotech, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- VLP Biotech, Inc. - Brief VLP Biotech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of VLP Biotech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of VLP Biotech, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the VLP Biotech, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate VLP Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of VLP Biotech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the VLP Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with VLP Biotech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of VLP Biotech, Inc. and identify potential opportunities in those areas.

Table Of Contents

VLP Biotech, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
VLP Biotech, Inc. Snapshot 4
VLP Biotech, Inc. Overview 4
Key Information 4
Key Facts 4
VLP Biotech, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
VLP Biotech, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
VLP Biotech, Inc. - Pipeline Products Glance 9
VLP Biotech, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
VLP Biotech, Inc. - Drug Profiles 10
Alzheimer's Disease Vaccine 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
HCV Vaccine 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
M2-Based Human Influenza Vaccine 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Malaria Vaccine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
VLP Biotech, Inc. - Pipeline Analysis 14
VLP Biotech, Inc. - Pipeline Products by Therapeutic Class 14
VLP Biotech, Inc. - Pipeline Products by Target 15
VLP Biotech, Inc. - Pipeline Products by Molecule Type 16
VLP Biotech, Inc. - Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
Coverage 18
Secondary Research 18
Primary Research 18
Expert Panel Validation 18
Contact Us 19
Disclaimer 19



List of Tables

VLP Biotech, Inc., Key Information 4
VLP Biotech, Inc., Key Facts 4
VLP Biotech, Inc. - Pipeline by Indication, 2013 6
VLP Biotech, Inc. - Pipeline by Stage of Development, 2013 7
VLP Biotech, Inc. - Monotherapy Products in Pipeline, 2013 8
VLP Biotech, Inc. - Preclinical, 2013 9
VLP Biotech, Inc. - Pipeline by Therapeutic Class, 2013 14
VLP Biotech, Inc. - Pipeline by Target, 2013 15
VLP Biotech, Inc. - Pipeline by Molecule Type, 2013 16



List of Figures

VLP Biotech, Inc. - Pipeline by Top 10 Indication, 2013 6
VLP Biotech, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 14
VLP Biotech, Inc. - Pipeline by Top 10 Target, 2013 15
VLP Biotech, Inc. - Pipeline by Top 10 Molecule Type, 2013 16



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.